Tetanus Prophylaxis

What it is. Tetanus is an acute, often fatal neuromuscular disease caused by the exotoxin tetanospasmin, produced by Clostridium tetani, a Gram-positive, spore-forming, obligate anaerobe ubiquitous in soil, dust and animal and human faeces. It is not transmissible person to person. Spores enter through wounds and germinate in low-oxygen, devitalised tissue.

Why it concerns the orthopaedic surgeon. Open fractures, crush injuries, farm and soil trauma and burns are the classic tetanus-prone wounds, and prophylaxis is a routine, examinable part of open-fracture management. Because tetanus is entirely vaccine-preventable, every wound encounter is an opportunity for prophylaxis.

Who gets it. In countries with high vaccine coverage tetanus is rare, and the cases cluster in the elderly, the under-vaccinated, migrants and people who inject drugs. Seroprotection falls sharply after age 60, which makes the elderly the highest-risk group. The major burden lies in limited-resource settings, as neonatal and maternal tetanus.

From wound to spinal cord. After spores germinate in anaerobic tissue, C. tetani releases tetanospasmin, which enters peripheral motor nerve terminals and undergoes retrograde axonal transport to the spinal cord and brainstem. There it cleaves synaptobrevin (VAMP), blocking release of the inhibitory neurotransmitters GABA and glycine from Renshaw and other inhibitory interneurons.

What the patient suffers. With inhibition lost, motor neurons fire unopposed, and the result is rigidity and spasm. The toxin also affects autonomic neurons, causing sympathetic overactivity and instability. Incubation is 3-21 days, and the shorter the incubation and onset, the more severe the disease.

Why TIG timing is critical. TIG neutralises only circulating, unbound toxin. Once the toxin has been internalised and fixed to neurons it cannot be reversed: binding is effectively irreversible, and recovery requires the growth of new nerve terminals.

Wound categories. Wounds are classed as clean, tetanus-prone or high-risk, and the category sets the booster threshold and the need for TIG.

Disease severity. Established tetanus is graded clinically by Ablett, from mild to very severe.

Most prophylaxis decisions are made in an asymptomatic patient with a fresh wound. The clinical features matter for recognising established disease, and for the rare patient who presents late.

Generalised tetanus is the most common form:

• Trismus (lockjaw), the earliest sign in most cases
• Risus sardonicus, a fixed sardonic grin
• Irritability, muscle pain, neck and abdominal rigidity, and opisthotonus
• Reflex spasms triggered by light, noise or touch
• Autonomic instability: labile blood pressure, tachycardia, sweating

Consciousness is preserved throughout. Preserved consciousness with generalised rigidity and stimulus-triggered spasms after a wound is the hallmark of tetanus.

Other forms. Generalised disease is not the only presentation:

• Localised: rigidity confined to the injured region, which may precede generalised disease
• Cephalic: cranial nerve involvement after head or neck wounds or otitis, with a poor prognosis
• Neonatal: a floppy then rigid neonate who feeds poorly, days after unhygienic cord care

Tetanus is a clinical diagnosis. There is no single confirmatory test, and treatment must not await investigations.

Human TIG is the passive-immunisation agent of choice, but in many limited-resource settings it is scarce and the only product available is equine tetanus antitoxin (ATS), antibody raised in horses. The Blake analysis of 545 US cases found equine antitoxin and human TIG equally effective at reducing case fatality, so ATS is an acceptable substitute when human TIG cannot be obtained.

Why human TIG is preferred. It is homologous human IgG, so it carries no risk of serum sickness or anaphylaxis from foreign protein, and it needs no sensitivity testing before administration. Its long half-life gives weeks of cover from a single 250-500 IU dose.

The caveats with ATS. Heterologous horse protein risks immediate anaphylaxis and delayed serum sickness (type III) around 7-12 days later. The half-life is short, roughly 2 days, so a larger prophylactic dose of about 1500 IU is used. A test dose, adrenaline readily available and administration under observation are advised.

When neither is stocked. Pooled human intravenous immunoglobulin (IVIG) contains tetanus antibody and is an alternative source of passive immunity, the "TIG (or IVIG)" option noted in UK guidance. Whichever product is used, passive immunisation never replaces active vaccination, wound debridement and antibiotics.

The emergency-department audit by Brand and colleagues found that overtreatment (17 percent) was far more common than undertreatment (6 percent), and that a structured protocol reduces both. Why unnecessary tetanus toxoid is harmful, and not merely wasteful, is a favourite examiner probe.

The Arthus (type III) reaction. It is seen in hyperimmunised patients with already-high antitoxin who receive a booster too soon. Immune-complex deposition causes a large, painful, sometimes whole-limb local swelling a few hours to about a day after the dose, and it can be severe and mistaken for cellulitis.

Why minimum intervals exist. A patient given a tetanus-containing dose within the last 5 years does not need a wound booster, and repeating one adds reactogenicity without benefit. Routine over-boosting drives local reactions, fever and injection-site pain. This is the safety rationale behind the 5-year (tetanus-prone) and 10-year (clean) thresholds.

Expected reactions. Local injection-site pain, redness and swelling, low-grade fever and malaise are common, expected and self-limiting; genuine anaphylaxis to the toxoid itself is very rare. The practical message mirrors the algorithm: give a booster when the interval justifies it, and resist reflexively boosting a recently vaccinated patient.

When trismus, rigidity or generalised spasms follow a wound, tetanus must be distinguished from its mimics. The spatula test supports the diagnosis.

Two questions decide it. What type of wound is this, clean or tetanus-prone? And what is the vaccination history: fully vaccinated with 3 or more doses, or incomplete or unknown? The table answers both at once.

Open (compound) fractures are always tetanus-prone, regardless of how the wound looks. Give ADT if more than 5 years have passed since the booster and TIG if there have been fewer than 3 doses or the history is uncertain, with thorough debridement as an essential adjunct.

Farm injuries are high-risk, because the soil is heavily contaminated with spores. Keep a low threshold for TIG even if vaccination is uncertain, and emphasise completing the vaccine series. A patient with ongoing exposure may need tetanus boosters every 5 years.

Immunocompromised patients may not mount an adequate vaccine response, so the threshold for TIG is lower: give it for tetanus-prone wounds even if vaccination is up to date. Consider repeat vaccinations for the severely immunocompromised, and document the decision-making clearly.

Burns and frostbite are all tetanus-prone, because of their extensive devitalised tissue. ADT and TIG are given according to the standard algorithm, although major burns often receive TIG regardless of vaccination status, and prolonged wound healing may need repeat prophylaxis.

Documentation. Record each of these elements:

Where and why. Established tetanus is managed with ICU admission, anticipating respiratory compromise. The disease does not confer immunity, so active immunisation is part of treatment alongside the specific measures:

• Human TIG 3000-6000 IU IM (or 500 IU intrathecally in some protocols) to neutralise unbound toxin
• Wound debridement to remove the source of toxin and the anaerobic niche
• Metronidazole 500 mg IV 8-hourly to kill vegetative C. tetani
• Benzodiazepines such as diazepam for spasm and rigidity
• Magnesium sulphate as an adjunct for spasm and autonomic control

Supportive care. Secure the airway with early intubation or tracheostomy, and nurse the patient in a quiet, dark environment to reduce spasm triggers. Feed by NG or PEG tube, and give DVT prophylaxis for the prolonged immobility.

Global Epidemiology

• Vaccine-preventable, still endemic: tetanus persists worldwide, concentrated in low- and middle-income settings with low immunisation coverage and unhygienic wound/birth practices.
• Neonatal/maternal burden: an estimated ~58,000 neonatal deaths per year despite the WHO Maternal and Neonatal Tetanus Elimination Initiative; 24 countries had not eliminated maternal/neonatal tetanus as of 2014.
• High-income pattern: cases are now rare and cluster in older adults, the under-vaccinated, migrants and people who inject drugs - groups with waning or absent immunity.
• Age-related immunity gap: seroprevalence falls sharply after age 60, so the elderly are both more likely to lack protection and to suffer severe disease.

Side-by-Side Guideline Comparison

High- vs Limited-Resource Practice Variation

Surveillance Rather Than Registries

Unlike arthroplasty, tetanus has no implant registry; surveillance relies on national notifiable-disease systems (e.g. CDC NNDSS, UK UKHSA) and WHO global reporting, which track incidence, vaccination coverage and elimination status to guide programme priorities.

Related pages: Open Fracture Management is the commonest orthopaedic setting for this decision, and the critical point is that tetanus prophylaxis is a SEPARATE question from antibiotic prophylaxis and from debridement - giving cefazolin does not cover tetanus, and neither does a thorough washout, because the toxin acts before the organism is cleared; Gas Gangrene and Clostridial Myonecrosis is the other clostridial emergency arising from the same contaminated wound, and the two are distinguished at the bedside because myonecrosis destroys tissue locally while tetanus leaves the wound looking unremarkable and attacks the nervous system remotely; Foot Puncture Wounds are the archetypal tetanus-prone injury - deep, narrow, anaerobic, and routinely dismissed as trivial by the patient; Animal Bites and Human Bites and Fight Bite carry their own prophylaxis decisions alongside this one; Orthopaedic Gunshot Wounds and Ballistics and Crush Syndrome for the high-energy contaminated injuries where devitalised tissue makes the wound tetanus-prone by definition; Wound Healing and Wound Closure Techniques for the debridement and closure decisions that sit alongside prophylaxis; Compartment Syndrome because rigidity and pain in an injured limb has a mechanical explanation far more often than a neurological one, and it must be excluded before anyone reaches for tetanus; and Surgical Site Infection Prevention for the elective counterpart, where a clean surgical wound needs no tetanus cover at all.

The 6-hour wound threshold. The classic "more than 6 hours = tetanus-prone" cut-off is convention rather than robust trial data. Several authorities, including UK guidance, now de-emphasise a strict time limit and weight contamination, devitalised tissue and mechanism more heavily. Treat the age of the wound as one factor, not an absolute rule.

Point-of-care antibody testing. Rapid bedside tetanus immunoassays can reduce unnecessary boosters and TIG in patients with an uncertain history. Sensitivity at the protective threshold is imperfect, so a negative quick test should prompt prophylaxis, but a positive result is not yet universally trusted to withhold it.

Magnesium and intrathecal antitoxin. Magnesium reduces the need for sedative and spasm-control drugs but, in the largest RCT, did not reduce ventilation or mortality. Intrathecal or intramuscular human TIG and the optimal therapeutic antitoxin dose remain debated, with limited high-quality evidence.

Booster interval: 10 years or life-course. Some modelling suggests that after a complete childhood primary series plus adolescent and adult boosters, decennial boosters may be unnecessary in low-incidence settings, favouring fewer lifetime doses. Wound-driven boosting remains standard regardless of this debate.

1. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332(12):761-766. doi:10.1056/NEJM199503233321201. PMID: 7862178

2. Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed). 1985;291(6496):648-650. doi:10.1136/bmj.291.6496.648. PMID: 3928066

3. Blake PA, Feldman RA, Buchanan TM, et al. Serologic therapy of tetanus in the United States, 1965-1971. JAMA. 1976;235(1):42-44. doi:10.1001/jama.1976.03260270024017. PMID: 946000

4. Brand DA, Acampora D, Gottlieb LD, et al. Adequacy of antitetanus prophylaxis in six hospital emergency rooms. N Engl J Med. 1983;309(11):636-639. doi:10.1056/NEJM198309153091104. PMID: 6888430

5. Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-1443. doi:10.1016/S0140-6736(06)69444-0. PMID: 17055945

6. Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth. 2001;87(3):477-487. doi:10.1093/bja/87.3.477. PMID: 11517134

7. Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015;385(9965):362-370. doi:10.1016/S0140-6736(14)60236-1. PMID: 25149223

8. Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18(2):217. doi:10.1186/cc13797. PMID: 25029486

9. Centers for Disease Control and Prevention. Tetanus: For Clinicians. CDC. 2024. Available at: cdc.gov/tetanus/clinicians.html

10. UK Health Security Agency. Tetanus: The Green Book, Chapter 30. 2024. Available at: gov.uk/government/publications/tetanus-the-green-book-chapter-30

11. World Health Organization. Tetanus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(6):53-76.